

Cancer Support Solutions with Color and GRAIL

Comprehensive cancer support from screening and navigation through survivorship care.

Four in 10 adults will develop cancer in their lifetime,¹ and nearly 70% of cancers have no recommended screening.² Because cancer affects nearly every workforce, employers want to support employees while managing rising cancer-related costs.

We're partnering with Color and GRAIL, leaders in cancer care who reflect our commitment to whole-person care, supporting employees' physical, emotional and long-term well-being with peace of mind and guidance throughout their entire cancer journey, if diagnosed.



Why employers are investing in cancer solutions

- Earlier detection and faster care can reduce high-cost, late-stage claims
- Cancer navigation helps employees return to work sooner and with more support
- A proactive cancer strategy demonstrates a meaningful commitment to employee well-being

We are offering two solutions for employers to select to fit their employees' needs.



Cancer Navigation, Support & Screening with Color (Buy-Up)

Employers can choose one, two, or all three of Color's services:

- Earlier Detection and Prevention, including at-home cervical, prostate, and colorectal screenings and genetic testing for hereditary cancer risk
- Active Treatment Management
- Survivorship Care



Multi-Cancer Early Detection with GRAIL (Buy-Up)

- The Galleri[®] test is the only MCED test proven through a randomized controlled trial (RCT) to detect cancer earlier and reduce stage IV diagnoses^{3,4}
- The Galleri[®] test screens for 50+ cancer types, including those without routine screening^{5,6}
- Support services for positive test results

Cancer Navigation, Support & Screening with Color FAQs

Q Who is Color?

A Color is a virtual cancer clinic that provides oncologist-led support across the entire cancer journey, from early detection and diagnosis to treatment support and survivorship.

Color combines clinical expertise with timely access to care, helping members get care sooner. This approach supports better outcomes and helps reduce the burden cancer places on members, their families and employers. Color has been shown to increase screening adherence by up to 77% and accelerate time to confirmed diagnosis by 66%.

Q Does Color's solution offer navigation or direct clinical cancer care?

A Color provides both cancer navigation and direct clinical care, pairing personalized guidance with access.

Through Color Medical's nationwide team of oncologists, physicians, oncology nurses, dietitians, care advocates and survivorship specialists, members receive support with care coordination, treatment decisions, symptom management, testing, prescriptions and ongoing clinical care. Color also works closely with local providers and the Priority Health care management team to help ensure members receive timely, coordinated support.

Q Who is eligible?

A All employees aged 18+, as well as covered spouses and dependents enrolled in the employer's Priority Health plan. Support is available regardless of cancer type, stage, or where someone is in their cancer journey.

Q What programs does Color offer?

A Color offers three integrated programs:

Earlier Detection and Prevention

Color identifies high-risk individuals through a guideline-based clinical assessment and helps members complete appropriate cancer screenings based on recommendations from organizations such as USPSTF, ACS and NCCN. Members receive personalized screening plans, at-home screening options when appropriate and clinical follow-up for abnormal results.

Active Treatment Management

Members diagnosed with cancer receive support from an oncologist-led care team that works alongside local treating providers and the Priority Health care management team. Color helps coordinate care, manage symptoms, close care gaps, support treatment planning and provide access to clinical expertise throughout treatment.

Survivorship Care

After treatment, Color helps cancer survivors manage long-term health, monitor for recurrence, address treatment-related side effects, support mental and physical well-being, and successfully return to work and daily life through survivorship-focused clinical care.

Q What are the program costs for Color?

A The member cost-share is \$0. Below are the employer costs for the different programs.

Program	Billed amount through claims
Early Detection and Prevention	\$175 per engaged member per year \$65 per completed colorectal, prostate, cervical at-home screening \$299 per completed heredity cancer risk screening
Active Treatment Management	\$3,500 per engaged member per 6 months
Survivorship Care	\$1,000 per engaged member per 6 months

Q How does Color drive engagement and use?

A Through personalized outreach, at-home screening options and support from dedicated clinical care teams, Color helps employees take action and stay engaged, improving screening adherence and reducing fear and confusion.

Multi-Cancer Early Detection with GRAIL FAQs

Q Who is GRAIL?

A GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software and automation to screen for cancer before symptoms appear.

Q What is the GRAIL Galleri® multi-cancer early detection test?

A The Galleri test screens for multiple cancers and can be taken annually as a simple blood draw.^{7,8} The test can screen for many aggressive cancers before symptoms appear.⁹ In a clinical study, the Galleri test detected a signal shared by more than 50 types of cancer.⁷

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests. See [Important Safety Information and Laboratory/Test Information](#).

Q How does the Galleri test look for cancer?

A Cancers growing in the body shed DNA into the bloodstream. Although there are many types, the DNA fragments act like a unique fingerprint of cancer.^{7,10,11} The Galleri test can screen for many aggressive cancers before they become symptomatic,⁹ including those with no recommended screening.¹² With this unique "fingerprint", the Galleri test helps to provide direction to your provider on the cancer's origin and the next steps in diagnosis.¹³

Q Who is eligible for the GRAIL Galleri® test?

A All employees aged 50+ as well as those aged 35-49 who may have additional risks.

Q What is the price for the Galleri test?

A GRAIL's Galleri test costs \$699. This is billed through claims. Member cost-share is either \$0 or \$100, depending on the employer's plan selection.

Q How do members learn about GRAIL and the Galleri test?

A Members receive communication about GRAIL's Galleri test directly from GRAIL and through Priority Health plan co-

branded outreach tactics such as direct mail and email; company intranet, member portals and more.

Q How does a member order the Galleri test?

A After eligibility is confirmed, members will request the test from the member landing page.

Cancer Support Solutions FAQs

Q How do these solutions work together?

A Galleri is clinically proven to detect cancer earlier and reduce the incidence of stage IV cancer.¹⁴ Color provides comprehensive care and navigation for employees diagnosed with cancer at any stage.

Q Why should I purchase these solutions through Priority Health?

A Purchasing Color and GRAIL through Priority Health offers lower overall cost and a more connected experience. These solutions are designed to work with your health plan, helping members move more seamlessly from screening to next steps with support along the way.

Q Do I need to purchase both solutions?

A No. You can purchase one or both.

¹American Cancer Society. Cancer Facts & Figures 2025. American Cancer Society 2025. <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2025-cancer-facts-figures.html>

²Business Group on Health. 2025 Employer Health Care Strategy Survey Executive Summary. August 2024. <https://www.businessgrouphealth.org/en/Resources/2025-Employer-Health-Care-Strategy-Survey-Executive-Summary>

³Swanton C, Johnson P, Round T, et al. NHS-Galleri: primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening [presentation]. American Society of Clinical Oncology (ASCO) Annual Meeting; 2026 May 30; Chicago. https://grail.com/wp-content/uploads/2026/05/Swanton_ASCO-2026_NHS-Galleri_FINAL-Slides-05.26.2026.pdf

⁴GRAIL, Inc. Demonstrated performance. [Data on file: GA-2025-0257]

⁵Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. *Ann Oncol.* 2021 Sep;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806

⁶US Preventive Services Task Force. A,B,C grade recommendations, cancer, screenings [cited 2023 Oct 23]. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results

⁷Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. *Ann Oncol.* 2021;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806

⁸Patel A. Methylated DNA biomarkers and incident cancer in the American Cancer Society (ACS) Cancer Prevention Study-3 (CPS-3) cohort [presentation]. American Society of Clinical Oncology (ASCO) Annual Meeting; 2023 Jun 2-6. https://assets.grail.com/wp-content/uploads/2023/06/Patel_ASCO-2023_ACS-CPS-3-Biobank_oral-presentation_FINAL.pdf

⁹Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multi-cancer early detection (PATHFINDER): a prospective cohort study. *Lancet.* 2023;402(10409):1251-60. doi: 10.1016/S0140-6736(23)01700-2

¹⁰Thierry AR, El Messaoudi S, Gahan PB, et al. Origins, structures, and functions of circulating DNA in oncology. *Cancer Metastasis Rev.* 2016;35(3):347-76. doi: 10.1007/s10555-016-9629-x

¹¹Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. *Ann Oncol.* 2020;31(6):745-59. doi: 10.1016/j.annonc.2020.02.011

¹²US Preventive Services Task Force. A,B,C grade recommendations, cancer, screening [cited 2025 Mar 18]. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results

¹³Enhanced Cancer Signal Origin prediction. [GRAIL, Inc. Data on file: VV-TMF-59592]

¹⁴Swanton C, Johnson P, Round T, et al. NHS-Galleri: primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening [presentation]. American Society of Clinical Oncology (ASCO) Annual Meeting; 2026 May 30; Chicago. https://grail.com/wp-content/uploads/2026/05/Swanton_ASCO-2026_NHS-Galleri_FINAL-Slides-05.26.2026.pdf